

WEST PHARMACEUTICAL SERVICES INC
Form DEFA14A
April 14, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

West Pharmaceutical Services, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

West Pharmaceutical Services, Inc.

530 Herman O. West Drive
Exton, PA 19341
www.westpharma.com

April 13, 2017

Dear Shareholder:

We revised the proxy card for shareholders to use in conjunction with our 2017 Annual Meeting of Shareholders to take place on May 2, 2017. The sample proxy card distributed on March 22, 2017 and the voting options previously provided at www.proxyvote.com did not reflect the majority voting standard in our Bylaws. The majority vote requirement and treatment of abstentions is accurately described in our proxy statement on page 5.

We have included a revised proxy card with this letter and have revised the voting options at www.proxyvote.com. Consistent with the majority voting standard, the revised proxy card gives you the option to vote For, Against or Abstain with respect to each director individually. We are using Abstain, instead of Withhold to be more consistent with our Bylaws as well.

If you have not yet voted, please discard the previously provided proxy card and use the enclosed revised proxy card to vote your shares by mail, or follow the instructions on the revised proxy card to vote via the internet or by telephone.

If you have already voted on www.proxyvote.com and do not change your vote or you use the prior proxy card, a vote for a director indicated as Withhold will be treated as an Against vote for all purposes at the meeting. We encourage shareholders who intended to vote abstain or intended to withhold their vote rather than vote Against to revise their vote on www.proxyvote.com or complete a new proxy card by checking the box for Abstain.

The changes to the proxy card only impact the election of directors. There are no changes to the voting for the other proposals up for consideration at the meeting.

If you have any questions, or need assistance in voting your shares, please contact me at 610-594-3319.

As always, your vote is important, and we appreciate your attention to this matter. We apologize for any inconvenience.

Sincerely,
George L. Miller

West Pharmaceutical Services, Inc. • Global Partners with Daikyo Seiko. Ltd. and The West Company Mexico S.A. de C.V.
